Top Page
Neuren Pharmaceuticals Limited
(Sydney:NEU)
Neuren Pharmaceuticals Limited (NEU) vs. iShares MSCI Australia ETF (EWA)
Neuren Pharmaceuticals Limited Business Overview & Revenue Model
Neuren Pharmaceuticals Limited Earnings Call Summary
Neuren Pharmaceuticals Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.78M | 213.24M | 231.93M | 14.55M | 3.20M | 717.00K |
| Gross Profit | 190.80M | 213.22M | 205.17M | 14.54M | 3.19M | 711.00K |
| EBITDA | 186.02M | 175.57M | 199.26M | -670.00K | -10.98M | -9.90M |
| Net Income | 149.06M | 142.04M | 157.08M | 184.00K | -7.79M | -9.19M |
Balance Sheet | ||||||
| Total Assets | 331.25M | 409.71M | 247.97M | 43.27M | 40.06M | 24.95M |
| Cash, Cash Equivalents and Short-Term Investments | 299.54M | 222.24M | 228.54M | 40.18M | 36.78M | 24.19M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.98M | 45.80M | 42.76M | 1.68M | 803.00K | 753.00K |
| Stockholders Equity | 323.27M | 363.90M | 205.21M | 41.59M | 39.25M | 24.20M |
Cash Flow | ||||||
| Free Cash Flow | 137.56M | -11.28M | 184.88M | 3.58M | -9.98M | -8.08M |
| Operating Cash Flow | 137.57M | -11.27M | 184.93M | 3.60M | -9.97M | -8.08M |
| Investing Cash Flow | -82.28M | 4.13M | -211.49M | -19.00K | -10.00K | -6.00K |
| Financing Cash Flow | -48.63M | -8.78M | 3.62M | -2.00K | 22.18M | 19.14M |
Neuren Pharmaceuticals Limited Technical Analysis
Neuren Pharmaceuticals Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$552.21M | 15.23 | 15.90% | 0.38% | 7.76% | 1.55% | |
71 Outperform | AU$2.11B | 14.29 | 54.79% | ― | 12.35% | 26.73% | |
55 Neutral | AU$3.26B | -19.37 | -18.95% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$582.12M | -9.36 | -35.86% | ― | ― | -19.21% | |
41 Neutral | AU$249.60M | -25.63 | -89.70% | ― | 42.05% | -0.84% | |
41 Neutral | AU$76.13M | -5.26 | -42.68% | ― | ― | 63.46% |
Neuren Pharmaceuticals Limited Corporate Events
Neuren Pharmaceuticals has confirmed to the ASX that recent information disclosed by its partner Acadia Pharmaceuticals on projected DAYBUE net sales, including a substantial increase in expected 2028 revenue versus 2025 guidance, is materially important for Neuren’s share price because royalties and milestones from DAYBUE are its only current source of product income. The company detailed the timeline of when it became aware of Acadia’s updated projections, outlined how it complied with continuous disclosure obligations by rapidly reviewing Acadia’s announcements, analyst forecasts and internal models before releasing its own market update, and asserted it has reasonable grounds to reference a projection of approximately US$700 million in global DAYBUE sales in 2028, relying on Acadia’s regulated disclosures in the US.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals reported that its partner Acadia Pharmaceuticals is projecting global net sales of Rett syndrome therapy DAYBUE to reach about US$700 million in 2028, underpinned by the US rollout of the new DAYBUE STIX powder formulation, enhanced US commercial infrastructure, and anticipated international expansion including potential European approval. Since the 2023 US launch, more than 2,000 Rett patients have been treated with DAYBUE, 12‑month treatment persistence has improved to 55%, the diagnosed US Rett population has grown to roughly 6,000 patients, and regulatory and clinical milestones are advancing with DAYBUE oral solution now approved in Israel and a Phase 3 trofinetide trial in Japan expected to deliver top-line data between late 2026 and early 2027, collectively strengthening Neuren’s commercial and clinical position in rare neurological disorders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals has announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in the peer-reviewed journal Neurology Genetics, with the study reporting that the treatment was well tolerated and associated with meaningful improvements in key symptoms as observed by clinicians and caregivers. These Phase 2 data underpin the design of Neuren’s ongoing Koala Phase 3 trial in the United States, a randomized, placebo-controlled study targeting about 160 pediatric patients with Phelan-McDermid syndrome, a rare disorder with no approved therapies and a significant unmet medical need, and the program benefits from US FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations, reinforcing Neuren’s position in the rare neurodevelopmental disease space.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals has secured Health Canada approval for its Clinical Trial Application for the Koala Phase 3 trial of NNZ-2591 in children aged 3 to 12 with Phelan-McDermid syndrome, allowing Canadian sites to be added to what is the first-ever Phase 3 study in this rare disorder. The trial, which already has US FDA IND clearance, is now enrolling at two activated sites in the United States on both coasts, and the expanded North American footprint marks a significant operational step in advancing NNZ-2591 through late-stage development, potentially strengthening Neuren’s position in the rare paediatric neurodevelopmental disease market and offering new hope to patients and families facing limited treatment options.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals announced that its partner, Acadia Pharmaceuticals, has received FDA approval for DAYBUE STIX, a new powder formulation of trofinetide for Rett syndrome, offering patients and caregivers more flexibility and choice. This approval, based on bioequivalence studies, ensures comparable efficacy and safety to the existing oral solution. DAYBUE STIX is expected to be available in early 2026, with Neuren receiving royalties on sales, potentially impacting its market position and providing new options for stakeholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals announced a one-month administrative delay in the FDA’s pre-IND meeting for their drug candidate NNZ-2591, now rescheduled for late January 2026. This delay may impact the timeline for developing treatments for hypoxic ischemic encephalopathy (HIE), highlighting the challenges in advancing therapies for rare neurological disorders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals Limited has announced the quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective November 25, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve market liquidity, which could positively impact its operations and industry positioning.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.20 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals Limited has released an investor presentation highlighting their commitment to enhancing the lives of people with neurodevelopmental disabilities. The presentation includes forward-looking statements, emphasizing the potential risks and uncertainties in drug development, regulatory processes, and clinical trials, which could impact the company’s operations and stakeholder interests.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
Neuren Pharmaceuticals reported record net sales of US$101.1 million for DAYBUE™ in Q3 2025, marking an 11% increase from Q3 2024. The company experienced significant growth in patient referrals and community-based prescriptions, with over 1,000 patients receiving shipments for the first time. Neuren’s royalty income also saw a substantial rise, and the company anticipates further growth potential in the US market. Additionally, Acadia, Neuren’s partner, has narrowed its full-year sales guidance and is expanding its market reach with ongoing trials and supply programs in multiple regions.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.